Antibody-drug conjugates (ADCs) represent a promising cancer treatment modality designed to deliver highly potent cytotoxic ...

SELLAS has announced positive data from preclinical studies identifying the ASXL1 mutation as a predictor of response to ...

A new method can improve treatment for patients with chronic myeloid leukaemia by predicting which medication will be most effective. The method also works for other forms of cancer where resistance ...

All cell lines were analyzed for presence of ASXL1 mutations and other genetic markers. High efficacy was prespecified as IC50 100 nM, significantly lower than the standard threshold definition for an ...

ISM5411 is designed to directly regulate the intestinal immune microenvironment so that the drug simultaneously reduces the gut inflammation seen in IBD while also promoting the repair of the ...

ESK-001, out of the 3 molecules, has the fullest target inhibition of TYK2 as measured by IC50 and IC90. This gives ESK-001 the ability to potentially increase efficacy with comparable dosing.

A new method can improve treatment for patients with chronic myeloid leukemia by predicting which medication will be most ...

Lower IC50 values signify greater potency. Out of the 16 compounds tested, 14 showed strong inhibitory activity measuring under 40 µM, indicating high potential. The most effective compound had a ...

Despite risks related to early-stage IP and low trading volume, SKYE's promising IP and near-term catalysts justify a ...